Orofacial pain management: current perspectives

Marcela Romero-Reyes, James M Uyanik, Marcela Romero-Reyes, James M Uyanik

Abstract

Some of the most prevalent and debilitating pain conditions arise from the structures innervated by the trigeminal system (head, face, masticatory musculature, temporomandibular joint and associated structures). Orofacial pain (OFP) can arise from different regions and etiologies. Temporomandibular disorders (TMD) are the most prevalent orofacial pain conditions for which patients seek treatment. Temporomandibular disorders include a number of clinical problems that involve the masticatory musculature, the temporomandibular joint (TMJ) or both. Trigeminal neuropathic pain conditions can arise from injury secondary to dental procedures, infection, neoplasias, or disease or dysfunction of the peripheral and/or central nervous system. Neurovascular disorders, such as primary headaches, can present as chronic orofacial pain, such as in the case of facial migraine, where the pain is localized in the second and third division of the trigeminal nerve. Together, these disorders of the trigeminal system impact the quality of life of the sufferer dramatically. A multidisciplinary pain management approach should be considered for the optimal treatment of orofacial pain disorders including both non-pharmacological and pharmacological modalities.

Keywords: TMD; headache; neuropathic; orofacial; pain; trigeminal.

Figures

Figure 1
Figure 1
Jaw N-stretch with vapocoolant spray. Notes: The patient is instructed to place the tip of the tongue on the roof of the mouth just behind the frontal teeth (like saying the letter “N”) and to open – stretching the mandible while the spray is directed towards the face (masseter muscle region) in an upward motion.
Figure 2
Figure 2
Temporomandibular joint injection.
Figure 3
Figure 3
Maxillary stabilization splint.
Figure 4
Figure 4
Relationship between temporomandibular disorders and headache. Notes: Extracranial nociceptive inputs arising from craniofacial structures as a result of a temporomandibular disorder, as well as cervical input from the cervical muscles, may influence the activation of the trigeminovascular system. The commonality is that these nociceptive inputs converge on the TNC in the same way as do intracranial nociceptive inputs arising from the dural blood vessels and higher centers. Abbreviations: C2, C2 region of the cervical spinal cord; PAG, ventrolateral periaqueductal gray; RVM, rostral ventromedial medulla; SPG, sphenopalatine ganglion; SuS, superior salivatory nucleus; TG, trigeminal ganglion; TMJ, temporomandibular joint; TNC, trigeminal nucleus caudalis; VII, facial nerve; VI, ophthalmic branch of the trigeminal nerve; V3, mandibular branch of the trigeminal nerve.

References

    1. Okeson JP. Bell’s Orofacial Pains. The Clinical Management of Orofacial Pain. 6th ed. Carol Stream, IL: Quintessence Publishing Co, Inc; 2005.
    1. Okeson JP. The Classification of Orofacial Pains. Oral Maxillofac Surg Clin North Am. 2008;20(2):133–144.
    1. McNeill C. Temporomandibular Disorders: Guidelines for Classification, Assesment, and Management. 2nd ed. Chicago, IL: Quintessence Publishing Co, Inc; 1993.
    1. Dworkin SF. Temporomandibular disorder (TMD) pain-related disability found related to depression, nonspecific physical symptoms, and pain duration at 3 international sites. J Evid Based Dent Pract. 2011;11(3):143–144.
    1. Dworkin SF, Huggins KH, LeResche L, et al. Epidemiology of signs and symptoms in temporomandibular disorders: clinical signs in cases and controls. J Am Dent Assoc. 1990;120(3):273–281.
    1. Solberg W, Woo M, Houston J. Prevalence of mandibular dysfunction in young adults. J Am Dent Assoc. 1979;98(1):25–34.
    1. Rasmussen OC. Description of population and progress of symptoms in a longitudinal study of temporomandibular arthropathy. Scand J Dent Res. 1981;89(2):196–203.
    1. Könönen M, Waltimo A, Nyström M. Does clicking in adolescence lead to painful temporomandibular joint locking? Lancet. 1996;347(9008):1080–1081.
    1. Guarda-Nardini L, Piccotti F, Mogno G, Favero L, Manfredini D. Age-related differences in temporomandibular disorder diagnoses. Cranio. 2012;30(2):103–109.
    1. Simons DG, Travel JG, Simons LS. Myofascial Pain and Dysfunction: The Trigger Point Manual. Upper Half of Body. 2nd ed. Atlanta, GA: Lippincott Williams & Wilkins; 1998. p. 1.
    1. Sanitá PV, de Alencar Júnior FGP. Myofascial pain syndrome as a contributing factor in patients with chronic headaches. J Musculoskelet Pain. 2009;17(1):15–25.
    1. de Leeuw R. Temporomandibular Disorders. In: de Leeuw R, editor. Orofacial Pain Guidelines for Assesment, Diagnosis and Management. 4th ed. Hanover Park, IL: Quintessence Publishing Co, Inc; 2008. pp. 158–176. (The American Academy of Orofacial Pain).
    1. Clark GT, Seligman DA, Solberg WK, Pullinger AC. Guidelines for the examination and diagnosis of temporomandibular disorders. J Craniomandib Disord. 1989;3(1):7–14.
    1. Bezuur JN, Habets LL, Jimenez Lopez V, Naeije M, Hansson TL. The recognition of craniomandibular disorders – a comparison between clinical and radiographic findings in eighty-nine subjects. J Oral Rehabil. 1988;15(3):215–221.
    1. Ohrbach R, Gale EN. Pressure pain thresholds, clinical assessment, and differential diagnosis: reliability and validity in patients with myogenic pain. Pain. 1989;39(2):157–169.
    1. Mejersjö C, Carlsson GE. Long-term results of treatment for temporomandibular joint pain-dysfunction. J Prosthet Dent. 1983;49(6):809–815.
    1. Nickerson JW, Boering G. Natural course of osteoarthrosis as it relates to internal derangement of the temporomandibular joint. Oral Maxillofac Surg Clin North Am. 1989;1:27–45.
    1. Mejersjö C, Carlsson GE. Analysis of factors influencing the long-term effect of treatment of TMJ-pain dysfunction. J Oral Rehabil. 1984;11(3):289–297.
    1. Riley JL, 3rd, Myers CD, Currie TP, et al. Self-care behaviors associated with myofascial temporomandibular disorder pain. J Orofac Pain. 2007;21(3):194–202.
    1. Randolph CS, Greene CS, Moretti R, Forbes D, Perry HT. Conservative management of temporomandibular disorders: a posttreatment comparison between patients from a university clinic and from private practice. Am J Orthod Dentofacial Orthop. 1990;98(1):77–82.
    1. Graff-Radford SB. Myofascial pain: diagnosis and management. Curr Pain Headache Rep. 2004;8(6):463–467.
    1. Danzig WN, Van Dyke AR. Physical therapy as an adjunct to temporomandibular joint therapy. J Prosthet Dent. 1983;49(1):96–99.
    1. Kirk WS, Jr, Calabrese DK. Clinical evaluation of physical therapy in the management of internal derangement of the temporomandibular joint. J Oral Maxillofac Surg. 1989;47(2):113–119.
    1. Clark GT, Adachi NY, Dornan MR. Physical medicine procedures affect temporomandibular disorders: a review. J Am Dent Assoc. 1990;121(1):151–162.
    1. Carlson CR, Okeson JP, Falace DA, Nitz AJ, Anderson D. Stretch-based relaxation and the reduction of EMG activity among masticatory muscle pain patients. J Craniomandib Disord. 1991;5(3):205–212.
    1. Rodrigues D, Siriani AO, Bérzin F. Effect of conventional TENS on pain and electromyographic activity of masticatory muscles in TMD patients. Braz Oral Res. 2004;18(4):290–295.
    1. Reeves JL. EMG-biofeedback reduction of tension headache: a cognitive skills-training approach. Biofeedback Self Regul. 1976;1(2):217–225.
    1. Gangarosa L, Mahan PE. Pharmacologic management of TMD-MPDS. Ear Nose Throat J. 1982;61:670–678.
    1. Gregg JM, Rugh JD. Pharmacological therapy. In: Mohl NDZ, George A, Carlsson, Gunnar E, Rugh, John D, editors. A Textbook of Occlusion. Chicago, IL: Quintessence; 1983. pp. 351–375.
    1. Song PC, Schwartz J, Blitzer A. The emerging role of botulinum toxin in the treatment of temporomandibular disorders. Oral Dis. 2007;13(3):253–260.
    1. Graff-Radford SB. Regional myofascial pain syndrome and headache: principles of diagnosis and management. Curr Pain Headache Rep. 2001;5(4):376–381.
    1. Ernberg M, Hedenberg-Magnusson B, List T, Svensson P. Efficacy of botulinum toxin type A for treatment of persistent myofascial TMD pain: a randomized, controlled, double-blind multicenter study. Pain. 2011;152(9):1988–1996.
    1. Guarda-Nardini L, Stecco A, Stecco C, Masiero S, Manfredini D. Myofascial pain of the jaw muscles: comparison of short-term effectiveness of botulinum toxin injections and fascial manipulation technique. Cranio. 2012;30(2):95–102.
    1. Wenneberg B, Kopp S, Gröndahl HG. Long-term effect of intra-articular injections of a glucocorticosteroid into the TMJ: a clinical and radiographic 8-year follow-up. J Craniomandib Disord. 1991;5(1):11–18.
    1. Kopp S, Akerman S, Nilner M. Short-term effects of intra-articular sodium hyaluronate, glucocorticoid, and saline injections on rheumatoid arthritis of the temporomandibular joint. J Craniomandib Disord. 1991;5(4):231–238.
    1. Samiee A, Sabzerou D, Edalatpajouh F, Clark GT, Ram S. Temporomandibular joint injection with corticosteroid and local anesthetic for limited mouth opening. J Oral Sci. 2011;53(3):321–325.
    1. Stoll ML, Good J, Sharpe T, et al. Intra-articular corticosteroid injections to the temporomandibular joints are safe and appear to be effective therapy in children with juvenile idiopathic arthritis. J Oral Maxillofac Surg. 2012;70(8):1802–1807.
    1. El-Hakim IE, Abdel-Hamid IS, Bader A. Tempromandibular joint (TMJ) response to intra-articular dexamethasone injection following mechanical arthropathy: a histological study in rats. Nt J Oral Maxillofac Surg. 2005;34(3):305–310.
    1. Toller PA. Use and misuse of intra-articular corticosteroids in treatment of temporomandibular joint pain. Proc R Soc Med. 1977;70(7):461–463.
    1. Divine JG, Zazulak BT, Hewett TE. Viscosupplementation for knee osteoarthritis: a systematic review. Clin Orthop Relat Res. 2007;455:113–122.
    1. Li XD, Shi ZD, Tian WD. An outcome analysis of two methods of intra-capsular injection of sodium hyaluronate for temporomandibular disorders. Hua Xi Kou Qiang Yi Xue Za Zhi. 2004;22(2):135–137. Chinese.
    1. Manfredini D, Piccotti F, Guarda-Nardini L. Hyaluronic acid in the treatment of TMJ disorders: a systematic review of the literature. Cranio. 2010;28(3):166–176.
    1. Herman CR, Schiffman EL, Look JO, Rindal DB. The effectiveness of adding pharmacologic treatment with clonazepam or cyclobenzaprine to patient education and self-care for the treatment of jaw pain upon awakening: a randomized clinical trial. J Orofac Pain. 2002;16(1):64–70.
    1. Silberstein SD. Preventive migraine treatment. Neurol Clin. 2009;27(2):429–443.
    1. Clark GT. A critical evaluation of orthopedic interocclusal appliance therapy: effectiveness for specific symptoms. J Am Dent Assoc. 1984;108(3):364–368.
    1. Clark GT. A critical evaluation of orthopedic interocclusal appliance therapy: design, theory, and overall effectiveness. J Am Dent Assoc. 1984;108(3):359–364.
    1. Tsuga K, Akagawa Y, Sakaguchi R, Tsuru H. A short-term evaluation of the effectiveness of stabilization-type occlusal splint therapy for specific symptoms of temporomandibular joint dysfunction syndrome. J Prosthet Dent. 1989;61(5):610–613.
    1. Kreiner M, Betancor E, Clark GT. Occlusal stabilization appliances. Evidence of their efficacy. J Am Dent Assoc. 2001;132(6):770–777.
    1. Fricton J, Look JO, Wright E, et al. Systematic review and meta-analysis of randomized controlled trials evaluating intraoral orthopedic appliances for temporomandibular disorders. J Orofac Pain. 2010;24(3):237–254.
    1. Klasser GD, Greene CS. Oral appliances in the management of temporomandibular disorders. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;107(2):212–223.
    1. Fricton J. Myogenous temporomandibular disorders: diagnostic and management considerations. Dent Clin North Am. 2007;51(1):61–83.
    1. Clark GT, Beemsterboer PL, Solberg WK, Rugh JD. Nocturnal electromyographic evaluation of myofascial pain dysfunction in patients undergoing occlusal splint therapy. J Am Dent Assoc. 1979;99(4):607–611.
    1. Dube C, Rompre PH, Manzini C, Guitard F, de Grandmont P, Lavigne GJ. Quantitative polygraphic controlled study on efficacy and safety of oral splint devices in tooth-grinding subjects. J Dent Res. 2004;83(5):398–403.
    1. Koh H, Robinson PG. Occlusal adjustment for treating and preventing temporomandibular joint disorders. Cochrane Database Syst Rev. 2003;(1):CD003812.
    1. Parameters of care for oral and maxillofacial surgery. A guide for practice, monitoring and evaluation (AAOMS Parameters of Care-92). American Association of Oral and Maxillofacial Surgeons. J Oral Maxillofac Surg. 1992;50(7 Suppl 2):i–xvi. 1–174. [No authors listed]
    1. Nitzan DW, Dolwick MF, Martinez GA. Temporomandibular joint arthrocentesis: a simplified treatment for severe, limited mouth opening. J Oral Maxillofac Surg. 1991;49(11):1163–1167. discussion 1168–1170.
    1. Dimitroulis G, Dolwick MF, Martinez A. Temporomandibular joint arthrocentesis and lavage for the treatment of closed lock: a follow-up study. Br J Oral Maxillofac Surg. 1995;33(1):23–27.
    1. Buckley MJ, Merrill RG, Braun TW. Surgical management of internal derangement of the temporomandibular joint. J Oral Maxillofac Surg. 1993;51(1 Suppl 1):20–27.
    1. Blaustein D, Heffez L. Diagnostic arthroscopy of the temporomandibular joint. Part II. Arthroscopic findings of arthrographically diagnosed disk displacements. Oral Surg Oral Med Oral Pathol. 1988;65(2):135–141.
    1. Elder C, Ritenbaugh C, Aickin M, et al. Reductions in pain medication use associated with traditional Chinese medicine for chronic pain. Perm J. 2012;16(3):18–23.
    1. Ritenbaugh C, Hammerschlag R, Calabrese C, et al. A pilot whole systems clinical trial of traditional Chinese medicine and naturopathic medicine for the treatment of temporomandibular disorders. J Altern Complement Med. 2008;14(5):475–487.
    1. Shen YF, Younger J, Goddard G, Mackey S. Randomized clinical trial of acupuncture for myofascial pain of the jaw muscles. J Orofac Pain. 2009;23(4):353–359.
    1. Romero-Reyes M, Graff-Radford S. Is there hope for chronic pain and headache? Headache. 2007;47(8):1262–1271.
    1. Lipton JA, Ship JA, Larach-Robinson D. Estimated prevalence and distribution of reported orofacial pain in the United States. J Am Dent Assoc. 1993;124(10):115–121.
    1. Marbach JJ. Medically unexplained chronic orofacial pain. Temporomandibular pain and dysfunction syndrome, orofacial phantom pain, burning mouth syndrome, and trigeminal neuralgia. Med Clin North Am. 1999;83(3):691–710.
    1. Kitt CA, Gruber K, Davis M, Woolf CJ, Levine JD. Trigeminal neuralgia: opportunities for research and treatment. Pain. 2000;85(1):3–7.
    1. Sarlani E, Balciunas BA, Grace EG. Orofacial pain – Part I: assessment and management of musculoskeletal and neuropathic causes. AACN Clin Issues. 2005;16(3):333–346.
    1. Sarlani E, Balciunas BA, Grace EG. Orofacial Pain – Part II: assessment and management of vascular, neurovascular, idiopathic, secondary, and psychogenic causes. AACN Clin Issues. 2005;16(3):347–358.
    1. Dworkin RH, O’Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85(Suppl 3):S3–S14.
    1. Zakrzewska JM. Medical management of trigeminal neuropathic pains. Expert Opin Pharmacother. 2010;11(8):1239–1254.
    1. Reisner L, Pettengill CA. The use of anticonvulsants in orofacial pain. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001;91(1):2–7.
    1. Martin WJ, Forouzanfar T. The efficacy of anticonvulsants on orofacial pain: a systematic review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;111(5):627–633.
    1. Bramwell BL. Bs Pharm Rph. Topical orofacial medications for neuropathic pain. Int J Pharm Compd. 2010;14(3):200–203.
    1. Baad-Hansen L. Atypical odontalgia – pathophysiology and clinical management. J Oral Rehabil. 2008;35(1):1–11.
    1. Patel SB, Boros AL, Kumar SK. Atypical odontalgia – an update. J Calif Dent Assoc. 2012;40(9):739–747.
    1. Merrill RL, Graff-Radford SB. Trigeminal neuralgia: how to rule out the wrong treatment. J Am Dent Assoc. 1992;123(2):63–68.
    1. Lutz J, Linn J, Mehrkens JH, et al. Trigeminal neuralgia due to neurovascular compression: high-spatial-resolution diffusiontensor imaging reveals microstructural neural changes. Radiology. 2011;258(2):524–530.
    1. Jannetta PJ. Arterial compression of the trigeminal nerve at the pons in patients with trigeminal neuralgia. J Neurosurg. 1967;26(1:Suppl):159–162.
    1. Bakshi R, Lerner A, Fritz JV, Sambuchi GD. Vascular compression in trigeminal neuralgia shown by magnetic resonance imaging and magnetic resonance angiography image registration. Arch Neurol. 2001;58(8):1290–1291.
    1. Matsuka Y, Fort ET, Merrill RL. Trigeminal neuralgia due to an acoustic neuroma in the cerebellopontine angle. J Orofac Pain. 2000;14(2):147–151.
    1. Feinerman DM, Goldberg MH. Acoustic neuroma appearing as trigeminal neuralgia. J Am Dent Assoc. 1994;125(8):1122–1125.
    1. Jensen TS, Rasmussen P, Reske-Nielsen E. Association of trigeminal neuralgia with multiple sclerosis: clinical and pathological features. Acta Neurol Scand. 1982;65(3):182–189.
    1. Fromm GH, Terrence CF, Chattha AS. Baclofen in the treatment of trigeminal neuralgia: Double-blind study and long-term follow-up. Ann Neurol. 1984;15(3):240–244.
    1. Zakrzewska JM, Chaudhry Z, Nurmikko TJ, Patton DW, Mullens EL. Lamotrigine (lamictal) in refractory trigeminal neuralgia: results from a double-blind placebo controlled crossover trial. Pain. 1997;73(2):223–230.
    1. Obermann M. Treatment options in trigeminal neuralgia. Ther Adv Neurol Disord. 2010;3(2):107–115.
    1. Singh PM, Kaur M, Trikha A. An uncommonly common: glossopharyngeal neuralgia. Ann Indian Acad Neurol. 2013;16(1):1–8.
    1. Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Prepared by the International Association for the Study of Pain, Subcommittee on Taxonomy. Pain Suppl. 1986;3:S1–S226. [No authors listed]
    1. Marks PV, Purchas SH. Life-threatening glossopharyngeal neuralgia. Aust N Z J Surg. 1992;62(8):660–661.
    1. Katusic S, Williams DB, Beard CM, Bergstralh EJ, Kurland LT. Epidemiology and clinical features of idiopathic trigeminal neuralgia and glossopharyngeal neuralgia: similarities and differences, Rochester, Minnesota, 1945–1984. Neuroepidemiology. 1991;10(5–6):276–281.
    1. Olds MJ, Woods CI, Winfield JA. Microvascular decompression in glossopharyngeal neuralgia. Am J Otol. 1995;16(3):326–330.
    1. Merrill RL. Head and neck pain. Seminars in Anesthesia, Perioperative Medicine, and Pain. 1997;16(4):280–291.
    1. Mathews GJOJ. Painful traumatic neuroma. Surg Clin North Am. 1972;52(5):1313–1324.
    1. Lee EJ, Calcaterra TC, Zuckerbraun L. Traumatic neuromas of the head and neck. Ear Nose Throat J. 1998;77(8):670–674.
    1. Derry S, Sven-Rice A, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2013;2:CD007393.
    1. Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth. 2011;107(4):490–502.
    1. H D, Wellish M, Gilden D. Topical ketamine treatment of postherpetic neuralgia. Neurology. 2003;60(8):1391.
    1. Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain. 2009;10(9):895.
    1. Merrill RL. Orofacial pain mechanisms and their clinical application. Dent Clin North Am. 1997;41(2):167–188.
    1. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders. Cephalalgia. (3rd ed) 2013;33(9):629–808. beta version.
    1. Peñarrocha M, Bandrés A, Peñarrocha M, Bagán JV. Lower-half facial migraine: a report of 11 cases. J Oral Maxillofac Surg. 2004;62(12):1453–1456.
    1. Daudia AT, Jones NS. Facial migraine in a rhinological setting. Clin Otolaryngol Allied Sci. 2002;27(6):521–525.
    1. Stewart WF, Ricci JA, Chee E, Morganstein D. Lost productive work time costs from health conditions in the United States: results from the American Productivity Audit. J Occup Environ Med. 2003;45(12):1234–1246.
    1. Akerman S, Holland PR, Goadsby PJ. Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci. 2011;12(10):570–584.
    1. May A, Goadsby PJ. The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. J Cereb Blood Flow Metab. 1999;19(2):115–127.
    1. McNaughton FL, Feindel W. Innervation of intracranial structures: a reappraisal. In: Rose FC, editor. Physiological aspects of clinical neurology. Oxford: Blackwell Scientific; 1977. pp. 279–293.
    1. Andreou AP, Summ O, Charbit AR, Romero-Reyes M, Goadsby PJ. Animal models of headache: from bedside to bench and back to bedside. Expert Rev Neurother. 2010;10(3):389–411.
    1. Bartsch T, Goadsby PJ. The trigeminocervical complex and migraine: current concepts and synthesis. Curr Pain Headache Rep. 2003;7(5):371–376.
    1. Goadsby PJ, Lipton RB, Ferrari MD. Migraine – current understanding and treatment. N Engl J Med. 2002;346(4):257–270.
    1. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28(2):183–187.
    1. Goadsby PJ. Migraine, allodynia, sensitisation and all of that …. Eur Neurol. 2005;53(Suppl 1):10–16.
    1. Burstein R, Levy D, Jakubowski M. Effects of sensitization of trigeminovascular neurons to triptan therapy during migraine. Rev Neurol (Paris) 2005;161(6–7):658–660.
    1. Durham PL. Calcitonin gene-related peptide (CGRP) and migraine. Headache. 2006;46(Suppl 1):S3–S8.
    1. Oshinsky ML. Insights from experimental studies into allodynia and its treatment. Curr Pain Headache Rep. 2006;10(3):225–230.
    1. Obermann M, Mueller D, Yoon MS, Pageler L, Diener H, Katsarava Z. Migraine with isolated facial pain: a diagnostic challenge. Cephalalgia. 2007;27(11):1278–1282.
    1. Silberstein SD, Lipton RB, Dalessio DJ, editors. Wolff’s Headache And Other Head Pain. 7th ed. New York: Oxford University Press; 2001. pp. 478–479.
    1. Benoliel R, Elishoov H, Sharav Y. Orofacial pain with vascular-type features. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997;84(5):506–512.
    1. Bernstein C, Burstein R. Sensitization of the trigeminovascular pathway: perspective and implications to migraine pathophysiology. J Clin Neurol. 2012;8(2):89–99.
    1. Nicholson R, Buse DC, Andrasik F, Lipton RB. Nonpharmacologic treatments for migraine and tension-type headache: how to choose and when to use. Curr Treat Options Neurol. 2011;13(1):28–40.
    1. Pistoia F, Sacco S, Carolei A. Behavioral therapy for chronic migraine. Curr Pain Headache Rep. 2012;17(1):1–8.
    1. Akerman S, Romero-Reyes M. Insights into the pharmacological targeting of the trigeminocervical complex in the context of treatments of migraine. Expert Rev Neurother. 2013;13(9):1041–1059.
    1. Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E, Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78(17):1346–1353.
    1. Silberstein S, Kori S. Dihydroergotamine: a review of formulation approaches for the acute treatment of migraine. CNS Drugs. 2013;27(5):385–394.
    1. Sprenger T, Goadsby P. Migraine pathogenesis and state of pharmacological treatment options. BMC Med. 2009;7:71.
    1. Buzzi MG, Moskowitz MA. Evidence for 5-HT1B/1D receptors mediating the antimigraine effect of sumatriptan and dihydroergotamine. Cephalalgia. 1991;11(4):165–168.
    1. Rapoport A, Winner P. Nasal delivery of antimigraine drugs: clinical rationale and evidence base. Headache. 2006;46:S192–S201.
    1. Carleton SC, Shesser RF, Pietrzak MP, et al. Double-blind, multicenter trial to compare the efficacy of intramuscular dihydroergotamine plus hydroxyzine versus intramuscular meperidine plus hydroxyzine for the emergency department treatment of acute migraine headache. Ann Emerg Med. 1998;32(2):129–138.
    1. Treatment of migraine attacks with sumatriptan. The Subcutaneous Sumatriptan International Study Group. N Engl J Med. 1991;325(5):316–321. [No authors listed]
    1. Humphrey PP, Feniuk W. Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol Sci. 1991;12(12):444–446.
    1. Shields KG, Goadsby PJ. Serotonin receptors modulate trigeminovascular responses in ventroposteromedial nucleus of thalamus: a migraine target? Neurobiol Dis. 2006;23(3):491–501.
    1. Ma QP. Co-localization of 5-HT(1B/1D/1F) receptors and glutamate in trigeminal ganglia in rats. Neuroreport. 2001;12(8):1589–1591.
    1. Ma QP, Hill R, Sirinathsinghji D. Colocalization of CGRP with 5-HT1B/1D receptors and substance P in trigeminal ganglion neurons in rats. Eur J Neurosci. 2001;13(11):2099–2104.
    1. Smith D, Shaw D, Hopkins R, et al. Development and characterisation of human 5-HT1B- or 5-HT1D-receptor specific antibodies as unique research tools. J Neurosci Methods. 1998;80(2):155–161.
    1. Longmore J, Shaw D, Smith D, et al. Differential distribution of 5HT1D- and 5HT1B-immunoreactivity within the human trigemino-cerebrovascular system: implications for the discovery of new anti-migraine drugs. Cephalalgia. 1997;17(8):833–842.
    1. Smith D, Hill RG, Edvinsson L, Longmore J. An immunocytochemical investigation of human trigeminal nucleus caudalis: CGRP, substance P and 5-HT1D-receptor immunoreactivities are expressed by trigeminal sensory fibres. Cephalalgia. 2002;22(6):424–431.
    1. Castro ME, Pascual J, Romón T, del Arco C, del Olmo E, Pazos A. Differential distribution of [3H]sumatriptan binding sites (5-HT1B, 5-HT1D and 5-HT1F receptors) in human brain: focus on brainstem and spinal cord. Neuropharmacology. 1997;36(4–5):535–542.
    1. Levy D, Jakubowski M, Burstein R. Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists. Proc Natl Acad Sci U S A. 2004;101(12):4274–4279.
    1. Burstein R, Jakubowski M. Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. Ann Neurol. 2004;55(1):27–36.
    1. Smith TR, Sunshine A, Stark SR, Littlefield DE, Spruill SE, Alexander WJ. Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache. 2005;45(8):983–991.
    1. Mathew NT, Landy S, Stark S, et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache. 2009;49(7):971–982.
    1. Dodick D, Lipton RB, Martin V, et al. Triptan Cardiovascular Safety Expert Panel Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache. 2004;44(5):414–425.
    1. Ho T, Ferrari M, Dodick D, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008;372:2115–2123.
    1. Färkkilä M, Diener HC, Géraud G, et al. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol. 2012;11(5):405–413.
    1. Ferrari MD, Färkkilä M, Reuter U, et al. European COL-144 Investigators Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan – a randomised proof-of-concept trial. Cephalalgia. 2010;30(10):1170–1178.
    1. Lance JW, Goadsby PJ. Mechanism and Management of Headache. 7th ed. Philadelphia, PA: Elsevier Butterworth Heinemann; 2005.
    1. Gady J, Ferneini EM. Botulinum toxin A and headache treatment. Conn Med. 2013;77(3):165–166.
    1. Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C, BOTOX CDH Study Group Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache. 2005;45(4):293–307.
    1. Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburgh AM, BOTOX North American Episodic Migraine Study Group Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Headache. 2007;47(4):486–499.
    1. Dodick DW, Turkel CC, DeGryse RE, et al. PREEMPT Chronic Migraine Study Group Onabotulinumtoxin A for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50(6):921–936.
    1. Mueller O, Diener HC, Dammann P, et al. Occipital nerve stimulation for intractable chronic cluster headache or migraine: a critical analysis of direct treatment costs and complications. Cephalalgia. 2013 Jun 28; Epub.
    1. Silberstein SD, Dodick DW, Saper J, et al. Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia. 2012;32(16):1165–1179.
    1. Schurks M, Diener HC, Goadsby P. Update on the prophylaxis of migraine. Curr Treat Options Neurol. 2008;10(1):20–29.
    1. Rasmussen BK. Migraine and tension-type headache in a general population: precipitating factors, female hormones, sleep pattern and relation to lifestyle. Pain. 1993;53(1):65–72.
    1. Olesen J. Clinical and pathophysiological observations in migraine and tension-type headache explained by integration of vascular, supraspinal and myofascial inputs. Pain. 1991;46(2):125–132.
    1. Jensen R, Rasmussen BK, Pedersen B, Olesen J. Muscle tenderness and pressure pain thresholds in headache. A population study. Pain. 1993;52(2):193–199.
    1. Bendtsen L, Fernández-de-la-Peñas C. The role of muscles in tensiontype headache. Curr Pain Headache Rep. 2011;15(6):451–458.
    1. Fernández-de-Las-Peñas C, Alonso-Blanco C, Cuadrado ML, Pareja JA. Myofascial trigger points in the suboccipital muscles in episodic tension-type headache. Man Ther. 2006;11(3):225–230.
    1. Fernández-de-las-Peñas C, Alonso-Blanco C, Cuadrado ML, Gerwin RD, Pareja JA. Myofascial trigger points and their relationship to headache clinical parameters in chronic tension-type headache. Headache. 2006;46(8):1264–1272.
    1. Kaniecki RG. Tension-type headache. Continuum (Minneap Minn) 2012;18(4):823–834.
    1. Bendtsen L, Jensen R. Treating tension-type headache – an expert opinion. Expert Opin Pharmacother. 2011;12(7):1099–1109.
    1. Bendtsen L, Evers S, Linde M, Mitsikostas DD, Sandrini G, Schoenen J; EFNS. EFNS guideline on the treatment of tension-type headache – report of an EFNS task force. Eur J Neurol. 2010;17(11):1318–1325.
    1. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343–349.
    1. LeResche L. Epidemiology of temporomandibular disorders: implications for the investigation of etiologic factors. Crit Rev Oral Biol Med. 1997;8(3):291–305.
    1. Mitrirattanakul S, Merrill RL. Headache impact in patients with orofacial pain. J Am Dent Assoc. 2006;137(9):1267–1274.
    1. Gonçalves DA, Bigal ME, Jales LC, Camparis CM, Speciali JG. Headache and symptoms of temporomandibular disorder: an epidemiological study. Headache. 2010;50(2):231–241.
    1. Franco AL, Gonçalves DA, Castanharo SM, Speciali JG, Bigal ME, Camparis CM. Migraine is the most prevalent primary headache in individuals with temporomandibular disorders. J Orofac Pain. 2010;24(3):287–292.
    1. Goadsby PJ, Cohen AS, Matharu MS. Trigeminal autonomic cephalalgias: diagnosis and treatment. Curr Neurol Neurosci Rep. 2007;7(2):117–125.
    1. Leone M, Bussone G. Pathophysiology of trigeminal autonomic cephalalgias. Lancet Neurol. 2009;8(8):755–764.
    1. May A. Update on the diagnosis and management of trigemino-autonomic headaches. J Neurol. 2006;253(12):1525–1532.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner